Shots:

• AdoRx enters into a collaboration with J&J’s Lung Cancer Initiative & J&J Innovations for drug discovery and preclinical candidates. J&J to get an exclusive option to research- develop- and commercialize antagonists within AdoRx’s portfolio
• The focus of the agreement is to develop therapies with expansion of J&J’s footprints in oncology using AdoRx’s fit-for-purpose adenosine receptor antagonists
• AdoRx's fit-for-purpose receptor antagonists modulates high adenosine level present in the tumor targeting the adenosine pathway against cancer

Ref: PRNewswire | Image: Bioworld